JAK Inhibitors for the Treatment of Vitiligo

Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.

Related Content:

Vitiligo: Practical Considerations for a Changing Therapeutic LandscapeVitiligo

Raj Chovatiya, MD, PhD: Takeaways from New Data on Vitiligo, Atopic Dermatitis, HS Treatments

Iltefat Hamzavi, MD: Long-Term Implications of New Data on Upadacitinib for Nonsegmental Vitiligo

Oral Upadacitinib Significantly Reduces Facial, Total Nonsegmental Vitiligo Through 52 Weeks